Tranexamic Acid in Combination With Vancomycin or Gentamicin Has a Synergistic Effect Against Staphylococci

Antonio Benjumea¹, Marta Díaz-Navarro²,³, Rama Hafian⁴, Emilia Cercenado²,⁵, Mar Sánchez-Somolinos⁵, Javier Vaquero¹,³,⁶, Francisco Chana¹, Patricia Muñoz²,⁵,⁶ and María Guembe²,³*

¹ Department of Orthopaedic Surgery and Traumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ² Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³ Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ⁴ School of Biology, Universidad Complutense de Madrid, Madrid, Spain, ⁵ CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain, ⁶ School of Medicine, Universidad Complutense de Madrid, Madrid, Spain

Background: Tranexamic acid (TXA) is an antifibrinolytic agent applied in orthopedic surgery and has been proven to reduce post-surgery infection rates. We previously showed that TXA also had an additional direct antimicrobial effect against planktonic bacteria. Therefore, we aimed to evaluate whether it has a synergistic effect if in combination with antibiotics.

Materials and Methods: Three ATCC and seven clinical strains of staphylococci were tested against serial dilutions of vancomycin and gentamicin alone and in combination with TXA at 10 and 50 mg/ml. The standardized microtiter plate method was used. Minimal inhibitory concentrations (MICs) were calculated by standard visualization of well turbidity (the lowest concentration at which complete absence of well bacterial growth was observed by the researcher) and using the automated method (the lowest concentration at which ≥80% reduction in well bacterial growth was measured using a spectrophotometer).

Results: Tranexamic acid-10 mg/ml reduced the MIC of vancomycin and gentamicin with both the standard method (V: 1-fold dilution, G: 4-fold dilutions) and the automated turbidity method (vancomycin: 8-fold dilutions, gentamicin: 8-fold dilutions). TXA-50 mg/ml reduced the MIC of gentamicin with both the standard turbidity method (6-fold dilutions) and the automated turbidity method (1-fold dilutions). In contrast, for vancomycin, the MIC remained the same using the standard method, and only a 1-fold dilution was reduced using the automated method.

Conclusion: Ours was a proof-of-concept study in which we suggest that TXA may have a synergistic effect when combined with both vancomycin and gentamicin, especially at 10 mg/ml, which is the concentration generally used in clinical practice.

Keywords: tranexamic acid, bacterial growth, antimicrobial effect, synergy, in vitro model
INTRODUCTION

Periprosthetic joint infections (PJIs) are caused by bacterial biofilm that adheres to the prosthesis and hampers eradication of infection once established (Josse et al., 2019; Shoji and Chen, 2020). Therefore, preventive strategies are necessary to reduce the frequency of PJIs at the time of surgery (Kapadia et al., 2016; Romanò et al., 2017).

Tranexamic acid (TXA) is an antifibrinolytic agent used in daily clinical practice as it binds to plasminogen and enables blood clotting (Jennings et al., 2016; Draxler et al., 2019). Numerous studies support the use of this drug in surgical interventions, specifically in orthopedic surgery and...
We first tested serial dilutions of TXA from 5 to 50 mg/ml. Tranexamic Acid at Increasing
isolated from patients with PJIs.
strains of MSSA (n = 3), MRSA (n = 1), and MRSE (n = 3) isolated from patients with PJIs.

**Materials and Methods**

Ours was an in vitro experimental study carried out at Hospital General Universitario Gregorio Marañón, Madrid, Spain (Supplementary Material 1; Behzadi and Gajdacs, 2021).

We included 10 strains: three American Type Culture Collection (ATCC) strains (methicillin-susceptible *Staphylococcus aureus* [MSSA; ATCC29213], methicillin-resistant *Staphylococcus aureus* [MRSA; ATCC43300], and methicillin-resistant *Staphylococcus epidermidis* [MRSE; ATCC35984]), and seven high-biofilm-producing clinical strains of MSSA (n = 3), MRSA (n = 1), and MRSE (n = 3) isolated from patients with PJIs.

**Tranexamic Acid at Increasing Concentrations**

We first tested serial dilutions of TXA from 5 to 50 mg/ml diluted in sterile water to identify which TXA concentration/s best reduced bacterial turbidity. The solutions were kept at 2–4°C until use.

The procedure was performed following CLSI guidelines and using a microtiter plate (Clinical and Laboratory Standards Institute, 2018). The wells of a 96-well plate were inoculated with 50 µl of each microorganism in Müller-Hinton broth and treated with serial dilutions (from 5 to 50 mg/ml) of TXA (50 µl of twice the final dose in the well). Positive controls (bacterial suspension) were treated with 100 µl of sterile water, and negative controls (only Müller-Hinton broth) were treated with 100 µl of TXA 50 mg/ml. All the experiments were performed in triplicate. Plates were incubated at 37°C for 24 h.

**Calculation of Percentage Reduction in Turbidity**

We used a spectrophotometer (492 nm) to calculate the percentage reduction in turbidity of each well at each TXA concentration compared to the positive control.

**Tranexamic Acid Combined With Vancomycin and Gentamicin**

We then tested the effect of TXA at extreme concentrations where similar results were observed according to reduction in bacterial turbidity (10 and 50 mg/ml) in combination with serial dilutions of vancomycin (Merck KGaA, Darmstadt, Germany) (from 0.03 to 16 mg/L) and gentamicin (Merck KGaA, Darmstadt, Germany) (from 0.06 to 32 mg/L), which were also tested separately in parallel.

The procedure was performed following CLSI guidelines (32nd edition, 2018) and using a microtiter plate (Clinical and Laboratory Standards Institute, 2018). The wells of a 96-well plate were inoculated with 5 µl of a suspension of 10⁷ cfu/ml of each microorganism in a Müller-Hinton broth and treated with the following: 100 µl of vancomycin (from 0.03 to 16 mg/L) alone (100 µl) and in combination (50 µl of twice the final dose in the well) with 50 µl of TXA (10 and 50 mg/ml) and gentamicin (from 0.06 to 32 mg/L) alone (100 µl) and in combination (50 µl of twice

**TABLE 1** | MIC<sub>50</sub> for vancomycin and gentamicin alone and in combination with tranexamic acid (TXA) using the standard visualization method.

| Treatment       | *Staphylococcus aureus* MIC<sub>50</sub> (ranges) mg/L | MIC<sub>50</sub> fold reductions (no.) | *Staphylococcus epidermidis* MIC<sub>50</sub> (ranges) mg/L | MIC<sub>50</sub> fold reductions (no.) | Overall MIC<sub>50</sub> (ranges) mg/L | MIC<sub>50</sub> fold reductions (no.) |
|-----------------|-------------------------------------------------------|----------------------------------------|--------------------------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| Vancomycin      | 0.12 (0.05–0.25)                                       | 0                                      | 0.25 (0.05–0.5)                                        | 6                                      | 0.12 (0.05–0.5)                        | 6                                      |
| Vancomycin + TXA| 0.12 (0.05–0.25)                                       | 0                                      | 0.12 (0.05–0.25)                                       | 1                                      | 0.12 (0.05–0.25)                        | 1                                      |
| Vancomycin + TXA| 0.25 (0.12–0.25)                                       | NA*                                   | 0.25 (0.05–0.5)                                        | 0                                      | 0.25 (0.05–0.5)                        | 0                                      |
| Gentamicin      | 4 (0.25–16)                                            | 5                                      | 16 (0.5–32)                                            | 4                                      | 8 (0.25–32)                            | 4                                      |
| Gentamicin + TXA| 0.12 (0.06–0.25)                                       | 5                                      | 1 (0.06–2)                                             | 4                                      | 0.5 (0.06–2)                           | 4                                      |
| Gentamicin + TXA| 0.12 (0.06–0.25)                                       | 5                                      | 0.25 (0.06–0.5)                                        | 6                                      | 0.12 (0.06–0.5)                        | 6                                      |

TXA, tranexamic acid; MIC, minimal inhibitory concentration; NA, not applicable. *1-fold increase was observed.*
the final dose in the well) with 50 µl of TXA (at 10 and 50 mg/ml). Positive controls (bacterial suspension) were treated with 100 µl of sterile water, and negative controls (only Müller-Hinton broth) were treated with 100 µl of each highest antibiotic concentration. All the experiments were performed in triplicate. Plates were incubated at 37°C for 24 h.

**Calculation of Minimal Inhibitory Concentration**

We defined the Minimal Inhibitory Concentration (MIC) of each antibiotic tested, alone or in combination with TXA, using both the standard visualization of well turbidity and the automated turbidity method (Clinical and Laboratory Standards Institute, 2018).

**FIGURE 2** | Distribution of strains according to serial dilutions of vancomycin and gentamicin alone and in combination with tranexamic acid (TXA) using the standard visualization method. (A) Vancomycin. (B) Gentamicin.
For the standard visualization method, MIC was defined as the lowest concentration at which complete absence of well bacterial growth (compared to the positive control) was observed by the researcher (Clinical and Laboratory Standards Institute, 2018).

For the automated turbidity method, MIC was defined as the lowest concentration at which ≥80% reduction in well bacterial growth (compared to the positive control) was measured using a spectrophotometer at 492 nm.

As our objective was not to identify whether the strains were susceptible or resistant but to assess the possible synergistic effect of TXA, we did not take into consideration the lack of correlation between the MICs obtained by one method or the other. We used the automated turbidity method in addition to the standard visualization method, because it provided a higher MIC, which enabled us to better detect the synergistic effect of TXA starting from higher MICs than with the standard method.

**Data Analysis**

The effect of serial dilutions of TXA against planktonic bacteria was expressed as the mean percentage reduction in well turbidity compared to the positive control.

Minimal Inhibitory Concentration was expressed as the geometric mean (MIC50) with the corresponding ranges.

Data were expressed by combining the results from all species together and separately according to species (Staphylococcus aureus, N = 6, and Staphylococcus epidermidis, N = 4).

The data are collected in the repository C.0001228 of the ISCIII.

**RESULTS**

**Percentage Reduction in Well Turbidity When Tranexamic Acid Serial Dilutions Were Tested Against Planktonic Bacteria**

Overall, TXA at 5 mg/ml showed almost no antibacterial effect (mean percentage reduction in turbidity 4%), especially for S. aureus (0%) (Figures 1A,B).

Above 5 mg/ml, the mean percentage reduction in well turbidity ranged from 27.4 to 42.5% (Figures 1A,B).

In order to select the extreme concentrations at which similar percentage reductions were observed, we tested TXA 10 (35%) and 50 mg/ml (42.5%) in subsequent experiments.

The mean percentage reduction in well turbidity for TXA 10 mg/ml in the S. aureus strains and the S. epidermidis strains was, respectively, 35.7 and 33.5%. The mean percentage reduction in well turbidity for TXA 50 mg/ml in the S. aureus strains and the S. epidermidis strains was, respectively, 37.8 and 52.2% (Figures 1A,B).

**Minimal Inhibitory Concentration of Vancomycin and Gentamicin Alone and in Combination With Tranexamic Acid Calculated Using the Standard Visualization Method**

Using the standard visualization method, TXA-10 mg/ml reduced the MIC50 of vancomycin and gentamicin by 1- and 4-fold, respectively: TXA10-V, 0.12 mg/L vs. V, 0.25 mg/L and TXA10-G, 0.5 mg/L vs. G, 8 mg/L. TXA-50 mg/ml reduced the MIC50 of gentamicin (TXA50-G, 0.12 mg/L vs. G, 8 mg/L) by 6-fold, whereas the MIC50 of vancomycin remained unchanged (0.25 mg/L) (Table 1 and Figures 2A,B).

**Minimal Inhibitory Concentration of Vancomycin and Gentamicin Alone and in Combination With Tranexamic Acid Calculated Using the Automated Turbidity Method**

Using the automated turbidity method, TXA-10 mg/ml reduced the MIC50 of vancomycin and gentamicin by 8-fold: TXA10-V, 0.03 mg/L vs. V, 8 mg/L and TXA10-G, 0.12 mg/L vs. G, >32 mg/L. TXA-50 mg/ml reduced the MIC50 of vancomycin and gentamicin 1-fold: TXA50-V, 4 mg/L vs. V, 8 mg/L and TXA50-G, 16 mg/L vs. G, >32 mg/L (Table 2 and Figures 3A,B).

**Table 2 | MIC50 for vancomycin and gentamicin alone and in combination with tranexamic acid (TXA) using the automatized turbidity method.**

| Treatment               | Staphylococcus aureus MIC50 (ranges) mg/L | Staphylococcus epidermidis MIC50 (ranges) mg/L | Overall MIC50 (ranges) mg/L |
|-------------------------|------------------------------------------|-----------------------------------------------|-----------------------------|
| Vancomycin              | 4 (0.12–16)                              | 16 (16–16)                                    | 8 (0.12–16)                 |
| Vancomycin + TXA 10 mg/ml | 0.03 (0.03–0.06)                        | 0.00 (0.03–0.03)                              | 0.00 (0.03–0.06)            |
| Vancomycin + TXA 50 mg/ml | 0.12 (0.03–0.25)                       | 8 (0.03–16)                                   | 4 (0.03–16)                 |
| Gentamicin              | 16 (0.06–32)                             | 32 (32–32)                                    | 32 (0.06–32)                |
| Gentamicin + TXA 10 mg/ml | 0.06 (0.06–0.12)                       | 0.12 (0.06–0.25)                             | 0.12 (0.06–0.25)            |
| Gentamicin + TXA 50 mg/ml | 8 (0.06–32)                             | 16 (0.06–32)                                  | 16 (0.06–32)               |

TXA, tranexamic acid; MIC, minimal inhibitory concentration.
**FIGURE 3**

Distribution of strains according to serial dilutions of vancomycin and gentamicin alone and in combination with tranexamic acid (TXA) using the automated turbidity method. (A) Vancomycin. (B) Gentamicin.
DISCUSSION

In combination with vancomycin and gentamicin, TXA showed a significant synergistic effect against the staphylococcal strains.

As we previously demonstrated that the effect of TXA on reduction in PJI rates was due to its direct effect by reducing bacterial growth (Benjumea et al., 2022), in addition to its indirect effect by reducing hematoma (Lohinai et al., 2015; Ruder and Springer, 2017; Draxler et al., 2019; Perez-Roman et al., 2019; Klement et al., 2020; Lacko et al., 2020; Sukeik et al., 2020; Yazd et al., 2020), we further investigated whether it could also have a synergistic effect if in combination with antibiotics. Therefore, we decided to test it with vancomycin and gentamicin, which are two of the most commonly used antibiotics in orthopedic surgery (Ratto et al., 2016; Gandhi et al., 2018; Myers and Lipof, 2020; Indelli et al., 2021; Parvizi, 2021).

We also previously observed that percentage reductions in bacterial growth were generally better when the concentration of TXA was lower (Benjumea et al., 2022). Therefore, in the present study, we tested the effect of TXA at serial dilutions. We demonstrated that the percentage reduction in well turbidity was similar between TXA concentrations of 10 and 50 mg/ml (range 35–42.5%). Also interesting was the finding that TXA at 5 mg/ml did not have an antimicrobial effect (4% reduction in well turbidity). Thus, we confirm that if the final volume of TXA was finally reached and absorbed in the joint did not reach at least 10 mg/ml, TXA would not have any antimicrobial effect at all. However, this is not a likely scenario, as the dose of TXA used by most authors in the literature is between 1 and 3 g. Therefore, if the joint volume of one knee is estimated at 131 (±53) ml, the intra-articular TXA dilution would be approximately 10–30 mg/ml (Hewitt and Stringer, 2008; Maniar et al., 2012; Matziolis et al., 2015; Jennings et al., 2016).

Although toxicity has been reported at TXA concentrations of >20 mg/ml (Parker et al., 2018; Sukur and Kucukdurmaz, 2018; McLean et al., 2019; Mortazavi et al., 2020; Balam et al., 2021; González Osuna et al., 2021; Ma et al., 2021; Touzopoulos et al., 2021), we decided to include a concentration of 50 mg/ml in our experiments in order to demonstrate that the synergistic effect was not dose-dependent. Using the standard visualization method, TXA 50 mg/ml reached higher fold reductions in gentamicin MIC50 in S. epidermidis (6 vs. 4 with TXA 10 mg/ml), although the same fold reduction in gentamicin MIC50 was observed for S. aureus (5 with TXA 10 and 50 mg/ml). Moreover, no synergistic effect was observed when TXA 50 mg/ml was combined with vancomycin on S. aureus or on S. epidermidis, whereas TXA 10 mg/ml reduced by 1-fold the vancomycin MIC50 in S. epidermidis. In addition, using the automated turbidity method, TXA 50 mg/ml reduced both the vancomycin and gentamicin MIC50 only by 1-fold compared with the 8-fold reduction for vancomycin and gentamicin with TXA 10 mg/ml.

Regarding the possible risk of using an anti-fibrinolytic drug in combination with an antibiotic during staphylococcal infection, to our knowledge, there are no studies answering the question of whether TXA combined with an antibiotic could produce or increase an adverse effect other than that which these drugs can produce by themselves. However, in orthopedic surgery, the use of systemic antibiotic treatment as prophylaxis of periprosthetic infection is widespread, including the use of antibiotic-loaded cement. On the other hand, TXA is commonly used both systemically and locally concomitantly in the same surgeries. In our clinical experience, we have not found an increase in local and/or systemic adverse effects (Wong et al., 2010; Poeran et al., 2014; Franchini et al., 2018).

Therefore, we can conclude that TXA 10 mg/ml showed a better synergistic effect with either vancomycin or gentamicin than TXA 50 mg/ml. However, whether the TXA mechanisms of action are direct or indirect is still unknown. Some studies have tried to answer this question. On the one hand, there is research that indicates the inhibitory effect of TXA, a lysine analog, on certain enzymes that favors biofilm formation (Lohinai et al., 2015). On the other hand, Draxler et al. (2019) conclude in their study on TXA and immune response that TXA has an immunomodulatory effect, altering the study of plasma cytokine levels, the number of immune cells, and the expression of multiple immunological markers.

The main limitation of the study is that we only tested 6 and 4 strains of S. aureus and S. epidermidis, respectively. Future studies are needed to validate our findings in a large sample size of clinical staphylococci strains. Furthermore, as we only tested a single dose, we do not know whether continuous doses could affect our results, as observed in the in vivo study by Zhang et al. (2021). In addition, we did not run growth curves or time-kill kinetic assays.

CONCLUSION

Our results suggest that TXA may reduce the MIC of vancomycin and gentamicin against staphylococci in an experimental planktonic model at the concentration generally used in clinical practice (10 mg/ml). This proof-of-concept study provides new insights regarding the preventive role of TXA in clinical practice.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

AUTHOR CONTRIBUTIONS

MG and FC were responsible for the organization and coordination of the trial. FC, JV, PM, and MG were the chief investigator and responsible for the data analysis. AB, MD-N, RH, EC, and MS-S developed the trial design and data collection. All authors contributed to wrote the final manuscript and approved the submitted version.
FUNDING

MG was supported by the Miguel Servet Program (ISCIII-MICINN, MSII18/00008) from the Health Research Fund (FIS) of the Carlos III Health Institute (ISCIII), Madrid, Spain. MD-N was supported by the Consejería de Educación, Juventud y Deporte de la Comunidad de Madrid and Fondo Social Europeo (PEJD-2020-AI_BMD-17971). The study was partially funded by grants from the Fundación Mutua Madrileña (MM12/01) and by grants from the FIS of the ISCIII (PI21/00344).

REFERENCES

Behzadi, P., and Gajdács, M. (2021). Writing a strong scientific paper in medicine and the biomedical sciences: a checklist and recommendations for early career researchers. *Biol. Futur.* 72, 395–407. doi: 10.1007/s42977-021-00095-2

Benjumea, A., Diaz-Navarro, M., Hafian, R., Sánchez-Somolinos, M., Vaquero, J., Chana, G., et al. (2022). Effect of Tranexamic Acid against Staphylococcus spp. and Cutibacterium acne Associated with Peri-Implant Infection: Results from an In Vitro Study. *Microbiol. Spectr.* 10:e0161221. doi: 10.1128/spectrum.0612-21

Bolam, S. M., O’Regan-Brown, A., Paul Monk, A., Musson, D. S., Cornish, J., and Munro, J. T. (2021). Toxicity of tranexamic acid (TXA) to intra-articular tissue in orthopaedic surgery: a scoping review. *Knee Surg. Sports Traumatol. Arthrosc.* 29, 1862–1871. doi: 10.1007/s00167-020-06219-7

Drazić, D. F., Yep, K., Hanafi, G., Winton, A., Daglas, M., Ho, H., et al. (2019). Tranexamic acid modulates the immune response and reduces postsurgical infection rates. *Blood Adv.* 3, 1598–1609. doi: 10.1182/bloodadvances.2019000992

Franchini, M., Mengoli, C., Cruciani, M., Bergamini, V., Presti, F., Marano, G., et al. (2018). Safety and efficacy of tranexamic acid for prevention of obstetric haemorrhage: an updated systematic review and meta-analysis. *Blood Transfus.* 16, 329–337. doi: 10.2450/2018.0026-18

Gandhi, R., Backstein, D., and Zywiol, M. G. (2018). Antibiotic-laden Bone Cement in Primary and Revision Hip and Knee Arthroplasty. *J. Am. Acad. Orthop. Surg.* 26, 727–734. doi: 10.5435/JAOS-D-17-00305

González Osuna, A., Rojas, L. F., Valencia, W. G., Atehortúa, L., Urrea, A. I., Kapadia, B. H., Berg, R. A., Daley, J. A., Fritz, J., Bhave, A., and Mont, M. A. (2016). Periprosthetic joint infection. *Blood Adv.* 10, 1602. doi: 10.1016/j.jocn.2019.05.029

Jennings, J. D., Solarz, M. K., and Haydel, C. (2016). Application of Tranexamic Acid in Trauma and Orthopedic Surgery. *Orthop. Clin. North Am.* 47, 137–143. doi: 10.1016/jocl.2015.08.014

Josse, J., Valour, F., Maali, Y., Diot, A., Batailler, C., Ferry, T., et al. (2019). Interaction Between Staphylococcal Biofilm and Bone: How Does the Presence of Biofilm Promote Prosthesis Loosening? *Front. Microbiol.* 10:1602. doi: 10.3389/fmicb.2019.01602

Kapadia, B. H., Berg, R. A., Daley, J. A., Fritz, J., Bhave, A., and Mont, M. A. (2016). Periprosthetic joint infection. *Lancet* 387, 386–394. doi: 10.1016/S0140-6736(14)6798-0

Klement, M. R., Padua, F. G., Li, W. T., Detweiler, M., and Parviz, J. (2020). Tranexamic Acid Reduces the Rate of Periprosthetic Joint Infection After Aseptic Revision Arthroplasty. *J. Bone Jt. Surg. Am. Volume* 102, 1344–1350. doi: 10.2106/JBJS.19.00925

Lacko, M., Jareúška, P., Schreierova, D., Lacková, A., and Gharaiéb, A. (2020). Tranexamic acid decreases the risk of revision for acute and delayed periprosthetic joint infection after total knee replacement. *Jt. Dis. Relat. Surg.* 31, 8–13. doi: 10.5606/jocr.2020.72061

Lohiain, Z., Keremi, B., Szőko, E., Tábi, T., Szabo, C., Tulassay, Z., et al. (2015). Biofilm Lysine Decarboxylase, a New Therapeutic Target for Periodontal Inflammation. *J. Periodontol.* 86, 1176–1184. doi: 10.1902/jop.2015.140490

Clinical and Laboratory Standards Institute (2018). *Performance Standards for Antimicrobial Susceptibility Testing*, 32nd Edn. Wayne, PA: Clinical and Laboratory Standards Institute, 362.

Ma, J., Lu, H., Chen, X., Wang, D., and Wang, Q. (2021). The efficacy and safety of tranexamic acid in high tibial osteotomy: a systematic review and meta-analysis. *J. Orthop. Surg. Res.* 16, 373. doi: 10.1186/s13018-021-02512-4

Maniar, R. N., Kumar, G., Singhi, T., Nayak, R. M., and Maniar, P. R. (2012). Tranexamic acid toxicity in human periarticular tissues. *Bone Jt. Res.* 1, 11–18. doi: 10.1002/bonej.2018-0181.B1

Melvin, J. S., Stryker, L. S., and Sierra, R. J. (2015). Tranexamic Acid in Hip and Knee Arthroplasty. *J. Am. Acad. Orthop. Surg.* 23, 732–740. doi: 10.5435/ JAaos-D-14-00223

Mortazavi, S. J., Sattartabar, B., Moharrami, A., and Kalantar, S. H. (2020). Intra-articular versus Intravenous Tranexamic Acid in Total Knee Arthroplasty: A Randomized Clinical Trial. *Arch. Bone Jt. Surg.* 8, 355–362.

Myers, T. G., and Lipof, J. S. (2020). Antibiotic Stewardship for Total Joint Arthroplasty in 2020. *J. Am. Acad. Orthop. Surg.* 28:e793–e802. doi: 10.5435/ JAAOS-D-19-00850

Parker, J. D., Lim, K. S., Kieser, D. C., Woodfield, T. B. F., and Hooper, G. J. (2018). Is tranexamic acid toxic to articular cartilage when administered topically? What is the safe dose? *Bone Jt. J.* 100, 404–412. doi: 10.5435/00000100B3. BJ2017-1135.R1

Parviz, J. G. T. (2021). *Consenso Internacional Sobre Infecciones Musculoesqueléticas. Parte II Cadera y Rodilla.* Madrid: Imaidea Interactiva, S.L.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2022.935646/full#supplementary-material
Romanò, C. L., De Vecchi, E., Bortolin, M., Morelli, I., and Drago, L. (2017). Hyaluronic Acid and Its Composites as a Local Antimicrobial/Antiadhesive Barrier. J. Bone Jt. Infect. 2, 63–72. doi: 10.7150/jbji.17705

Ruder, J. A., and Springer, B. D. (2017). Treatment of Periprosthetic Joint Infection Using Antimicrobials: Dilute Povidone-Iodine Lavage. J. Bone Jt. Infect. 2, 10–14.

Shoji, M. M., and Chen, A. F. (2020). Biofilms in Periprosthetic Joint Infections: A Review of Diagnostic Modalities, Current Treatments, and Future Directions. J. Knee Surg. 33, 119–131. doi: 10.1055/s-0040-1701214

Sukeik, M., Alshryda, S., Powell, J., and Haddad, F. S. (2020). The effect of tranexamic acid on wound complications in primary total Hip Arthroplasty: a meta-analysis. Orthop. Surg. 18, 53–61.

Sukur, E., and Kucukdurmaz, F. (2018). Comparison of Cytotoxic Effects of Intra-Articular Use of Tranexamic Acid versus Epinephrine on Rat Cartilage. Med. Sci. Monit. 24, 1166–1170. doi: 10.12659/msm.908560

Touzopoulos, P., Arvanitidis, K., Filidou, E., Tilkieridis, K., Karanikas, M., Kolios, G., et al. (2021). Is serum gentamicin concentration modified with autologous cell-saved blood transfusion after total knee arthroplasty using tranexamic acid? A randomised control trial. Orthop. Traumatol. 107:102794. doi: 10.1016/j.otsr.2020.102794

Waddell, B. S., Zahoor, T., Meyer, M., Ochsner, L., and Chimento, G. (2016). Topical Tranexamic Acid Use in Knee Periprosthetic Joint Infection Is Safe and Effective. J. Knee Surg. 29, 423–429. doi: 10.1055/s-0035-1564599

Wong, J., Abishami, A., El Beheiry, H., Mahomed, N. N., Roderick Davey, J., Gandhi, R., et al. (2010). Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial. J. Bone Jt. Surg. Am. 92, 2503–2513.

Yazdi, H., Klement, M. R., Hammad, M., Inoue, D., Xu, C., Goswami, K., et al. (2020). Tranexamic Acid Is Associated With Reduced Periprosthetic Joint Infection After Primary Total Joint Arthroplasty. J. Arthroplasty 35, 840–844. doi: 10.1016/j.arth.2019.10.029

Zhang, F. D. W., Wang, F., Yu, J., Jiang, F., Tang, J., Qian, Y., et al. (2021). The Topical Tranexamic Acid Have Potential Hazard of Promoting Biofilm Formation of Staphylococcus aureus in Microenvironment of the Prosthetic Joint. Biomed Res. Int. 2021:5748069. doi: 10.1155/2021/5748069

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Benjumea, Díaz-Navarro, Haifan, Cercenado, Sánchez-Somolinos, Vaquero, Chana, Muñoz and Guembe. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.